SynthesisFrontiers in pharmacology2026
Clinical characteristics, management, and outcome of tamoxifen-induced hyperlipidemia: a systematic review.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Evidence linking tamoxifen to hypertriglyceridemia (HTG) is mainly derived from case reports. This study aimed to evaluate clinical characteristics and provide evidence to improve identification and management. Methods: Databases including China National Knowledge Infrastructure (CNKI), Wanfang, VIP, Web of Science, PubMed, Embase, and Elsevier were searched up to 25 February 2026. Case reports and case series on tamoxifen-induced hypertriglyceridemia (HTG) were collected and descriptively analyzed. Results: A total of 49 patients (2 males, 47 females) were included, with a median age of 49 years (range 34-74). Acute pancreatitis (AP) occurred in 31 patients (63.3%). Median triglyceride (TG) levels increased from 274 mg/dL before treatment to 2,534 mg/dL after tamoxifen initiation. Median time to HTG onset was 6 months, and to AP symptoms 9 months. Compared with the non-AP group, the AP group was younger (median 47 vs. 50.5 years, (p = 0.005)), had a higher prevalence of hypertension (25.6% vs. 0%, (p = 0.029)), and had higher post-treatment TG levels (3,358 vs. 1,566 mg/dL, (p = 0.051)). Logistic regression identified younger age as an independent risk factor for AP, with risk decreasing by approximately 15% per year of age (OR 0.849, 95% CI 0.750-0.961, (p = 0.01)). In three patients who underwent rechallenge, HTG recurred significantly faster (median 17.5 days). Tamoxifen was discontinued in most patients (39/49), and 81.6% received lipid-lowering therapy. TG normalization time was shorter in the AP group (median 11.5 vs. 60 days, (p = 0.003)). Forty-six patients improved. One died of liver failure, one left the hospital voluntarily due to septic shock, and one had unreported outcome. Causality was judged "probable" in 85.7% (Naranjo scale). Conclusion: Tamoxifen-induced HTG is a significant and frequent risk factor for AP, which can be severe. Younger age is inversely correlated with AP risk. Close lipid monitoring, especially during the first year of treatment and in patients with metabolic disorders, is crucial. Prompt drug discontinuation, aggressive lipid-lowering therapy, and supportive care are key to management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.